TechnoPhage announced that it has provided TP-102, developed for the treatment of infected diabetic foot ulcers, for two compassionate use cases, which took place in July 2022, in Israel.

The product was recently evaluated in the scope of the Phase I/IIa clinical study that was carried out in the same country, but two gravely ill patients were not eligible to participate in the study. It was in this context that Dr. Michal Dekel asked Technophage to provide the product for compassionate use. Indeed, TP-102 is indicated for the treatment of diabetic foot ulcers infected by three bacteria, including Staphylococcus aureus, which was the agent responsible for the infections in these two patients.

The patients were both in a critical situation: the first suffered from an invasive infection that evolved from a diabetic foot ulcer, and the second had an infection in the Achilles tendon area caused by a bacteria resistant to antibiotics, being at that time already a candidate for amputation.

In an interview with the Portuguese journal Health News, the Israeli doctor spoke about the successful results of the compassionate use of TP-102 in the treatment of infected diabetic foot ulcers in these two patients, noting that “both patients improved dramatically”, and adding that in the present “they are fine and continue to be followed up in an outpatient clinic”.

Dra. Michal also explained that “the treatment of these infections is hampered by the inability of antibiotics to penetrate into the wounds”, with phage therapy having a decisive role in the clinical outcome of patients. “The phages have the advantage of being able to be applied topically, multiplying exactly where they are needed”, she guarantees.

In addition to the successful use in these two cases under a compassionate use regime, the TP-102 product has recently completed the Phase I/IIa Clinical Trial with good results. The company is already preparing the subsequent phases to evaluate the product’s safety and efficacy in a larger number of patients.

Technophage’s translation of the full interview can be accessed in the link.